Richard Simkin is a seasoned pharmaceutical executive with over 25 years of experience in commercial leadership, sales, and marketing within the healthcare sector. His career began at Reckitt Benckiser, where he held progressively senior roles in global sales and business development, contributing to the successful commercialization of several key products in the consumer health and pharmaceuticals divisions. Simkin played a pivotal role during the 2014 spin-off of Indivior PLC from Reckitt Benckiser, joining as a founding executive and leveraging his expertise to establish a robust commercial infrastructure for the newly independent company focused on treatments for opioid use disorder. As Chief Commercial Officer at Indivior Pharmaceuticals Inc. from 2014 to 2020, Simkin oversaw all aspects of the company's global commercial operations, including sales strategy, market access, pricing, and digital marketing. Under his leadership, Indivior achieved significant revenue growth, expanding its market share in the addiction treatment space through the successful launches of SUBLOCADE® and PERSERIS®, which together drove annual sales exceeding $1 billion by 2019. His strategic initiatives enhanced payer relationships, optimized distribution channels, and navigated complex regulatory environments, positioning Indivior as a leader in innovative therapies for substance use disorders. Post-Indivior, Simkin has continued to advise biotech firms on commercial transformation and serves on the boards of several healthcare startups. His achievements have been recognized with awards such as the PharmaVOICE 100 for commercial excellence, and he remains a sought-after speaker on scaling pharmaceutical businesses in niche therapeutic areas.